Overview

A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA

Status:
RECRUITING
Trial end date:
2026-10-19
Target enrollment:
Participant gender:
Summary
To study the safety and effectiveness of tofacitinib 2% cream in treating early-stage CTCL.
Phase:
PHASE2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
tofacitinib